HomeSample Page

Sample Page Title

On this new episode of omg OMx, Kate Stumpo speaks to Bruker’s Mike Greig concerning the unimaginable potential of mass spectrometry in pharma. Uncover chosen highlights, or watch the complete episode beneath:

Mike Greig | omg OMx Podcast | Ep. 9

What are some essential classes you will have discovered in your profession, and are there any essential those that have helped you alongside the best way?

After I began my profession in biotechnology, my boss was Wealthy Griffey. He ran our group like a Ph.D. program. Earlier than I left Isis Prescribed drugs, I had nearly 20 publications protecting all the things from gas-phase chemistry of nucleotides to structural evaluation of native mass spec.

Being in biotech within the Nineteen Nineties, you needed to be taught many various issues. You additionally needed to contribute to basic science to display to Isis that these completely different biotech corporations deserved funding. It was a good time to be in biotech. Even now, in a small biotech firm, it’s essential to be taught all the things to contribute meaningfully and make the corporate profitable.

Whereas at Isis Prescribed drugs, I had the chance to be a visiting scientist with Marshall’s group, which happened at an ASMS. At my first ASMS, I met Jared Rader and Chris Hendrickson. Chris Hendrickson is now the director of the MagLab.

I met them on an elevator at ASMS. We bought speaking and have become good buddies. About three ASMSs later, we mentioned mass spec and our respective fields. That is after I went to their lab and began working with them as a visiting scientist.

Is there a science “OMG” second, even when it isn’t mass spec associated, that made you’re keen on the sphere of chemistry?

I went to Buffalo Grove Excessive Faculty within the northwest suburbs of Chicago. I took AP chemistry with Dr. Bowles. He was a tremendous particular person — tremendous energetic and made the category very pleasant, which is kind of outstanding for an AP chemistry course.

A few weeks earlier than the Christmas break one 12 months, we did a saccharides experiment. We have been mixing all these compounds and made two ropes, a purple and a white. We twisted them up and he instructed us to place a bend in them. All people within the class all of the sudden realized that we had simply made sweet canes. That is how he turned science into sweet for us. It confirmed us that science may embody every kind of issues, and could be enjoyable and attractive.

What developments have you ever noticed within the fields that you’ve been in, whether or not in pharma or another sectors?

The developments in drug discovery all through my profession have been wonderful in the best way approaches, throughput, and pace have developed. What a single scientist can contribute now could be outstanding, primarily because of know-how and the web.

The great factor about working with Bruker now could be that I get to go to folks in different pharma and biotech labs and speak concerning the science they’re doing intimately. What everyone is doing in these labs is simply phenomenal at a person degree.

By way of mass spec, the developments within the usability and robustness of devices have been wonderful to witness. After I first began, I used a single quad instrument with fusion pumps. I needed to rebuild that instrument each different day to maintain it operating. Though this was nice as a result of I discovered so much about mass spec by constructing, rebuilding, and changing parts, I might not advocate it for a high-throughput lab.

Now, the devices, software program, {hardware}—all the things about mass spec is extra usable. Twenty years in the past, you’d by no means see devices in mass specs and biology labs. Now, they’re all over the place.

Picture Credit score: White_Fox/

Are you able to inform us extra concerning the evolution strategy of a drug?

Most locations begin with a illness or therapeutic space, and you then determine what your goal goes to be. There are numerous publications, akin to Time Journal, that say, “Oh, most cancers is cured. We discovered the subsequent goal,”. Whether or not it’s Time Journal, Analytical Chemistry, or Science, it’s a fixed bombardment of recent targets for oncology, coronary heart illness, or different therapeutic areas.

I primarily labored in oncology throughout my final 10 years at Pfizer, so I’m most conversant in that discipline. However you continually see all these targets which have the potential to remedy completely different forms of breast most cancers, in addition to different forms of most cancers. Subsequently, the very first thing we do in pharma is that we validate these targets.

As soon as a goal has been validated by means of a number of organic, analytical, and different strategies, we proceed with a high-throughput screening marketing campaign. Whereas this high-throughput screening marketing campaign goes on, there’s additionally plenty of work in biology, which incorporates analytical chemistry to determine the mechanism of motion.

If the mechanism of motion could be outlined, the possibilities of success in medical trials improve dramatically. The following stage entails progressing down the pipeline, getting a lead compound, and on the lookout for biomarkers. Having good biomarkers additionally will increase the possibility of medical success considerably.

As you progress downstream, you get into the preclinical or pre-human research. Then you definately progress to the human research part one trial. This part usually checks if the drug is tolerable to people. You then transfer to part two and part three the place the efficacy is evaluated and eventually, the drug is able to hit the market.

What are some important boundaries to the marketability of mass spectrometry within the pharma or biopharma business?

Mass spec is already extremely marketable to the pharma business. Virtually each single pharma lab has a mass-spec instrument in operation. To reinforce marketability, the hot button is to enhance the benefit of use and software program.

There are numerous core mass spec labs the place the folks within the lab are gearheads who need to do all the things with the instrument and do plenty of exploration. However, there are additionally recombinant protein labs the place the main target is on making proteins for venture groups, and so they merely need to look at and procure an correct mass of the intact protein.

These labs need the mass spec to be only a walkup instrument. There are already many walkup devices for chemistry and biology. So, ease of use is already there. Now, the one query is whether or not we will make these complicated experiments simpler to do and reproducible.

Most typical forms of experiments are already established. We at the moment are pushing into superior realms akin to top-down sequencing out of biofluids. Because the complexity of the samples will increase, the necessity for extra improvements will even improve.

In regards to the speaker

Mike Greig is Government Director and International Pharma/BioPharma Market at Bruker Scientific, LLC.

omg OMx host: Kate Stumpo, Senior Market Supervisor at Bruker


About Bruker Life Sciences Mass Spectrometry

Uncover new methods to use mass spectrometry to in the present day’s most urgent analytical challenges. Improvements akin to Trapped Ion Mobility (TIMS), smartbeam and scanning lasers for MALDI-MS Imaging that ship true pixel constancy, and eXtreme Decision FTMS (XR) know-how succesful to disclose Isotopic Tremendous Construction (IFS) signatures are pushing scientific exploration to new heights. Bruker’s mass spectrometry options allow scientists to make breakthrough discoveries and achieve deeper insights.



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments